biostudies-literatureLi NNCATS NIH HHSNIH Clinical CenterNCI NIH HHSNational Institutes of Health1240https://www.ebi.ac.uk/biostudies/studies/S-EPMC7393232biostudies-literatureUnknown10<b>Background:</b> The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based electric field-induced release and measurement (EFIRM) is liquid biopsy platform to that can directly detect mutation genes with a small volume of samples. Herein, we compared the effectiveness of longitudinal monitoring for the combination of epidermal growth factor receptor (<i>EGFR)</i> and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (<i>PIK3CA)</i> mutations between saliva-based EFIRM and plasma-based platforms (ddPCR and NGS) in two advanced NSCLC patients undergoing the treatment with osimertinib before Frontiers in oncologyLongitudinal Monitoring of <i>EGFR</i> and <i>PIK3CA</i> Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.PMC7393232U01 CA233370UH3 CA206126UH2 CA206126UH3 TR000923R21 CA239052Kim CYe LWong DTWGuha ULi FWei FChia DLi NCheng JfalseLongitudinal Monitoring of <i>EGFR</i> and <i>PIK3CA</i> Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.<b>Background:</b> The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based electric field-induced release and measurement (EFIRM) is liquid biopsy platform to that can directly detect mutation genes with a small volume of samples. Herein, we compared the effectiveness of longitudinal monitoring for the combination of epidermal growth factor receptor (<i>EGFR)</i> and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (<i>PIK3CA)</i> mutations between saliva-based EFIRM and plasma-based platforms (ddPCR and NGS) in two advanced NSCLC patients undergoing the treatment with osimertinib before 2020-01-01T00:00:00Z20202026-05-02T15:31:13.69Z2020-08-20T07:18:33ZS-EPMC73932323279349510.3389/fonc.2020.01240